Serial entrepreneur and precision medicine technologist to drive strategic agenda at BC Platforms
BC Platforms, a global leader in real world data, healthcare data management, and analytics, today announces the appointment of a new Chairman of the Board.
Alex is a seasoned executive with deep experience at the intersection of healthcare, life sciences, and information technology. He currently sits on the boards of two California-based companies he co-founded: Ryght (applying generative AI to clinical trials) and Chromacode (a cloud-based molecular diagnostics company). Alex also sits on the board of Gencove, an NGS analytics software platform provider based in New York. From 2017 to its acquisition in 2021 for $12B, Alex sat on the board of PRA Health Sciences, a 20,000-employee NASDAQ-listed Clinical Research Organization (CRO) that operated in over 80 countries.
From 2010 to 2017, Alex was SVP Strategic Initiatives at Illumina where he led the company’s nation-scale precision medicine program and its cloud computing efforts, developing one of the world’s most widely used bioinformatics platforms, BaseSpace. Alex came to Illumina through its acquisition of Helixis, a life sciences instrument company that he co-founded in 2007 and led as CEO.
From 2001 to 2007 he co-founded, and was CEO of, Luxtera, a leading silicon photonics company that was later acquired by Cisco Systems for $660M. Originally from Adelaide, Australia, Alex has a PhD in Electrical Engineering from the University of Adelaide, and an MBA from the Columbia Business School in New York.
BC Platforms’ new Chairman of the Board, Alex Dickinson, said, “I’m looking forward to driving BC Platforms’ strategic agenda, working with the remarkable team of industry visionaries committed to making the company a global leader, and trusted partner, in life sciences and healthcare. BC Platforms’ unique combination of a federated data network and support for multimodal data types makes it the ideal platform to enable insights from health data and the rapidly growing applications from training data sets for AI-driven drug development to integration of multiomic data into clinical workflows. BC Platforms’ proven technology enables faster and more cost-effective drug development and precision matching of treatments to patient needs.”
“Alex’s deep experience in M&A and his track record as a precision medicine evangelist will reinforce and accelerate BC Platforms’ strategy as a global technology enabler for real world data,” said Laurent Samama who has been acting Chairman of the Board.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
